Your session is about to expire
← Back to Search
CLE-100 for Antidepressants (SOLEO Trial)
SOLEO Trial Summary
This trial is testing a new medication called CLE-100 (oral esketamine) for treating Major Depressive Disorder (MDD) in people who have not responded well to standard antidepressants.
SOLEO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SOLEO Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Which individuals meet the eligibility criteria for enrollment in this research study?
"Individuals aged between 18 and 65 years with a history of antidepressant use are eligible to participate in this study. The research team aims to recruit a total of 90 volunteers."
At present, how many distinct locations are simultaneously conducting this experimental investigation?
"This study is actively ongoing at Clinical Site 105 in Lauderhill, Clinical Site 128 in Marlton, and Clinical Site 101 in Toms River, alongside an additional 4 undisclosed locations."
What are the risks associated with CLE-100 in individuals?
"In our assessment at Power, the safety rating for CLE-100 is 2 on a scale of 1 to 3. This Phase 2 trial has existing data supporting its safety profile but lacks evidence regarding its effectiveness."
Are patients currently being actively recruited for participation in this study?
"Affirmative. Records on clinicaltrials.gov confirm that recruitment for this trial is ongoing. The study was originally listed on March 18, 2024, and had its latest update recorded on April 1, 2024. In total, the research aims to enroll 90 participants distributed among four different sites."
Is the research study open to individuals who are above 70 years of age?
"Potential candidates for this study must be above 18 years of age and below 65 years of age to qualify for enrollment."
Share this study with friends
Copy Link
Messenger